Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Combination Ramucirumab and Erlotinib for NSCLC with EGFR Exon 19 or Exon 21 Mutations
Read More
Lung Cancer
Capmatinib for Patients with NSCLC with MET Exon 14 Mutation
Read More
Lung Cancer
Anti-TIGIT Antibody Tiragolumab plus Atezolizumab in Patients with PD-L1–Selected NSCLC
Read More
Lung Cancer
Phase 3 EMPOWER-Lung 1 Study of Cemiplimab in Advanced PD-L1–Positive NSCLC
Read More
Lung Cancer
Updated Analysis of PFS Data from Cohort G of KEYNOTE-021 in Nonsquamous NSCLC
Read More
Lung Cancer
Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC
Read More
Lung Cancer
ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC
Read More
Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Achieves Promising Responses in Resectable NSCLC (CheckMate-816)
Read More
Lung Cancer
Adjuvant Gefitinib versus Vinorelbine plus Cisplatin in Patients with Completely Resected Stage II to IIIA EGFR-Mutant NSCLC (ADJUVANT)
Read More
Lung Cancer
Stereotactic Body Radiotherapy versus Delayed Surgery for Early-Stage NSCLC
Read More
6
7
8
9
10
11
12
Page 9 of 12
Results 81 - 90 of 116
